Statistical Analysis Plan for the INTEnsive Care Bundle with Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial: A Stepped-Wedge Cluster Randomized Controlled Trial

Billot L.Song L.a,b· Hu X.c· Ma L.c· Ouyang M.a,b· Chen X.a· You C.c· Anderson C.S.a,b· on behalf of the INTERACT3 Investigators

Author affiliations

aThe George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia
bThe George Institute China at Peking University Health Sciences Center, Beijing, China
cDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Abstract of Protocols

Received: February 07, 2022
Accepted: August 03, 2022
Published online: September 05, 2022

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: https://www.karger.com/CED

Abstract

The third INTEnsive care bundle with blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT3) is an international, multicenter, stepped-wedge (4 phases/3 steps) cluster randomized trial involving 110 hospitals in mainly low- and middle-income countries during 2017–2022. The aim is to determine the effectiveness of a goal-directed care bundle of intensive blood pressure (BP) lowering, glycemic control, antipyrexia, and anticoagulation reversal treatment versus usual standard of care, in patients with acute intracerebral hemorrhage (ICH). After a “usual care” period, hospitals were randomly allocated to implementing care-bundle protocols for control targets (systolic BP <140 mm Hg; glucose 6.1–7.8/7.8–10.0 mmol/L according to diabetes mellitus status; temperature ≤37.5°C; normalization of anticoagulation). A sample size of 8,360 patients (mean 19 per phase per site) provides 90% power (α = 0.05) for a 5.6% absolute improvement in the primary outcome of scores on the modified Rankin scale at 6 months, analyzed by ordinal logistic regression. A detailed statistical analysis plan (SAP) was developed to prespecify the method of analysis for all outcomes and key variables collected in the trial. The primary analysis will use ordinal logistic regression adjusted for the stepped-wedge design. The SAP also includes planned sensitivity analyses, including covariate adjustments, missing data imputations, and subgroup analysis. This SAP allows transparent, verifiable, and prespecified analyses in consideration of the challenges in conducting the study during the COVID pandemic. It also avoids analysis bias arising from prior knowledge of the findings in determining the benefits and harms of a care bundle in acute ICH.

© 2022 S. Karger AG, Basel

References Zwierzyna M, Davies M, Hingorani AD, Hunter J. Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005. BMJ. 2018;361:k2130. Dammers R, Beck J, Volovici V, Anderson CS, Klijn CJM. Advancing the surgical treatment of intracerebral hemorrhage: study design and research directions. World Neurosurg. 2022;161:367–75. Hemorrhagic Stroke Academia Industry (HEADS) Roundtable Participants; Second HEADS Roundtable Participants. Recommendations for clinical trials in ICH: the second hemorrhagic stroke academia industry roundtable. Stroke. 2020;51(4):1333–8. Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ. 2015;350:h391. Song L, Hu X, Ma L, Chen X, Ouyang M, Billot L, et al. INTEnsive care bundle with blood pressure reduction in acute cerebral hemorrhage trial (INTERACT3): study protocol for a pragmatic stepped-wedge cluster-randomized controlled trial. Trials. 2021;22(1):943. Minhas JS, Moullaali TJ, Rinkel GJE, Anderson CS. Blood pressure management after intracerebral and subarachnoid hemorrhage: the knowns and known unknowns. Stroke. 2022;53(4):1065–73. Song L, Wang X, Ouyang M, Sun L, Chen X, Arima H, et al. Associations of an abnormal physiological score with outcomes in acute intracerebral hemorrhage: INTERACT2 study. Stroke. 2021;52(2):722–5. Parry-Jones AR, Sammut-Powell C, Paroutoglou K, Birleson E, Rowland J, Lee S, et al. An intracerebral hemorrhage care bundle is associated with lower case fatality. Ann Neurol. 2019;86(4):495–503. Ouyang M, Anderson CS, Song L, Jan S, Sun L, Cheng G, et al. Implementing a goal-directed care bundle after acute intracerebral haemorrhage: process evaluation for the third INTEnsive care bundle with blood pressure reduction in acute cerebral haemorrhage trial study in China. Cerebrovasc Dis. 2022;51(3):373–83. Barbui C, Cipriani A. Cluster randomised trials. Epidemiol Psych Sci. 2011;20(4):307–9. Kristunas C, Morris T, Gray L. Unequal cluster sizes in stepped-wedge cluster randomised trials: a systematic review. BMJ Open. 2017;7(11):e017151. Hemming K, Taljaard M, McKenzie JE, Hooper R, Copas A, Thompson JA, et al. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. BMJ. 2018;363:k1614. Article / Publication Details

First-Page Preview

Abstract of Protocols

Received: February 07, 2022
Accepted: August 03, 2022
Published online: September 05, 2022

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: https://www.karger.com/CED

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif